Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jun 4, 2008

165_ip_2008-06-04_c852cc63-9643-42f6-8f38-e3ac6d3cdba8.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Deutsche Bank German & Austrian Corporate Conference

Frankfurt/Main June 4, 2008

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Q&A Session

Q1 2008 – Strong Start into the Year

R
e
e
n
e
v
u		 \$
2
1
2
5
m
,		 8
%
+
N
i
t
e
n
c
o
m
e		 \$
1
8
6
m		 1
6
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
3		 1
5
%
+
  • X First Quarter fully in line with Company expectations
  • X Continued strong operating performance in North America
  • X Continued strong revenue growth in the International segment

Total Revenue Increased 8% to \$ 2,512 m *

* 4% growth at constant currency (cc)

Strong Growth Internationally of 13%cc

\$
i
i
l
l
i
n
m
o
n
s		 Q
1
2
0
0
7		 Q
1
2
0
0
8		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
8
3
,		 1
4
9
5
,		 1
%
f
f
f
A
d
j
d
h
l
h
i
b
i
t
t
t
s
e
o
r
e
s
a
e
o
e
p
e
r
s
o
n
s
n
e
s
s
u
u
u		 3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 2
7
7		 3
4
9		 2
6
%		 1
3
%
T
t
l
o
a		 1
6
0
7
,		 1
8
4
4
,		 %
5		 3
%
f
f
f
A
d
j
d
h
l
h
i
b
i
t
t
t
u
s
e
o
r
e
s
a
e
o
e
p
e
r
u
s
o
n
u
s
n
e
s
s		 6
%		 4
%

cc = constant currency

Deutsche Bank German Corporate Conference, June 4, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA 6

Dialysis Services - United States

Excellent External Revenue Growth – Twice the Market

\$
i
i
l
l
i
n
m
o
n
s		 Q
1
2
0
0
7		 Q
1
2
0
0
8		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
i
l.
I
l
R
)
t
n
c
n
e
r
n
a
e
e
n
e
v
u		 4
0
7		 8
6
9		 1
%
7		 9
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 6
0
5		 6
6
7		 1
9
%		 1
0
%
N
h
A
i
t
o
r
m
e
r
c
a		 1
5
3		 1
2
7		 1
2
%		 1
2
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 4
0
7		 4
9
5		 2
2
%		 9
%

cc = constant currency

Deutsche Bank German Corporate Conference, June 4, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA 8

Highlights

N
h
t
X
E
(
E
U
)
o
r
r
o
p
e
u
A
i
m
e
r
c
a
f
(
)
X
A
i
P
i
i
A
P
s
a
a
c
c
-
-		 X
C
f
i
d
h
i
d
1
2
%
t
t
t
t
o
n
n
e
r
e
e
n
e
g
r
o
m
o
m
e
n
m
n
p
r
o
c
s
o
u
v
u
w
u
u
X
L
h
d
P
D
L
i
b
C
l
t
a
u
n
c
e
n
e
w
e
r
y
y
c
e
r
X
A
i
M
f
t
n
e
m
a
a
n
a
g
e
m
e
n
o
c
u
s
X
N
b
l
i
i
P
h
L
(
C
d
i
A
J
K
D
j
l
)
2
t
t
e
p
c
a
o
n
o
n
o
s
o
a
r
e
s
n
o
r
n
a
w
u
u
y
u
E
r
o
p
e
u		 X
f
R
h
i
d
1
1
%
t
t
t
e
e
n
e
g
r
o
m
o
m
e
n
m
c
o
n
n
e
o
c
c
v
u
w
u
u
X
S
b
k
H
D
h
i
l
f
1
4
%
t
t
r
o
n
g
a
o
e
m
a
r
e
m
a
c
n
e
s
a
e
s
o
v
X
C
h
i
i
b
i
P
l
t
t
t
t
o
m
p
r
e
e
n
s
v
e
r
e
m
u
r
s
e
m
e
n
s
r
u
c
u
r
e
n
o
r
u
g
a
X
f
S
2
0
i
i
i
b
d
E
D
T
A
i
k
h
l
M
1
0
t
t
t
t
t
s
c
e
n
c
p
a
p
e
r
s
o
e
p
r
e
s
e
n
e
a
n
o
c
o
m
a
y
A
i
s
a
-
f
P
i
i
a
c
c		 X
S
k
h
f
8
%
t
t
t
t
t
t
r
o
n
g
s
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w
o
X
C
R
h
i
h
i
f
3
%
t
7
e
v
e
n
u
e
g
r
o
w
n
n
a
o
X
C
i
d
i
i
h
f
(
l.
J
)
1
3
%
t
t
o
n
n
e
m
p
r
e
s
s
e
r
e
e
n
e
g
r
o
o
c
c
e
c
a
p
a
n
u
v
v
u
w
x
X
F
i
F
M
E
I
i
i
D
i
l
i
N
i
(
F
I.
D
N
)
l
t
t
t
t
r
s
n
s
u
e
n
a
y
s
s
u
r
s
n
g
c
a
s
s

cc= constant currency

Financials and Outlook

Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 Q
1
2
0
0
7		 Q
1
2
0
0
8		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
3
2
1
,		 2
5
1
2
,		 *
8
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 3
6
5		 3
8
9		 7
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
7		 1
5
5
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 9
5		 8
3
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 2
7
0		 3
0
6		 1
3
%
I
T
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
0
3		 1
1
4
T
t
a
r
a
e
x		 3
8
0
%		 3
7
3
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 7 6
N
i
t
e
n
c
o
m
e		 1
6
0		 1
8
6		 1
6
%

* 4% growth at constant currency, 5% organic growth

Continued Solid Performance in All Segments

\$
i
i
l
l
i
n
m
o
n
s		 G
i
d
u
a
n
c
e
N
R
t
e
e
e
n
e
s
v
u		 \$
1
0
4
0
0
>
,
N
I
t
e
n
c
o
m
e		 \$
8
0
5
8
2
5
-
L
i
t
e
e
r
a
g
e
r
a
o
v
(
/
)
D
b
E
B
I
T
D
A
t
e		 2
8
<
C
i
l
E
d
i
t
t
a
p
a
x
p
e
n
u
r
e		 \$
6
5
0
7
5
0
~
-
A
i
i
i
t
c
q
s
o
n
s
u		 \$
1
0
2
0
5
5
~
-

Investment budget driven by further growth opportunities

Fresenius Medical Care

Midterm Strategy

Midterm Strategy / Goal

Expanded Global Presence Last 12 Months

* including clinics where FME has an interest of at least 10%

Dialysis Services Worldwide - Patients

Source: Company data

Global Patients by Region

2007

Sustainable Patient Growth of ~ 6% p.a.

~ 2 million patients expected by 2010

~ 4 million patients expected by 2025

Source: Company estimates

Dialysis Products Worldwide

  • •We clearly gained market share in HD
  • •Produced 75 Million Dialyzers in 2007
  • •Produced the Company's 500 Millionth Dialyzer
  • •RSI Acquisition to set standards in future technologies

Source: 2007 Company data / internal estimates

New Products 2008/2009

Integrated Patient Care Model – Clinic Centric

Our Leadership Model

Patient Care

Products

Drugs Therapy

Market Opportunity

2010 Revenue Target

Sustainable Growth of Earnings After Tax – Low to Mid-Teens per year

Our Growth Drivers

Targeted Revenue Growth in 2008 >7%

Thank You for your interest in Fresenius Medical Care !

Fresenius Medical Care

Q
1
2
0
0
8		 C
l
i
i
n
c		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
io
)
m
n
T
l
t
o
a		 2
2
9
7
,		 1
0
9
7
7
5
,		 6
2
7
G
h
t
r
o
w		 5
%
+		 5
%
+		 5
%
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
6
4
0
,		 1
2
2
6
9
1
,		 4
6
5
G
h
t
r
o
w		 4
%
+		 3
%
+		 4
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 6
5
7		 4
3
6
8
5
,		 2
0
8
G
h
t
r
o
w		 6
%
+		 8
%
+		 8
%
+
E
r
o
p
e
u		 3
7
5		 2
9
2
7
7
,		 1
0
7
L
i
A
i
t
a
n
m
e
r
c
a		 1
7
0		 1
8
2
4
6
,		 0
6
9
A
i
P
i
f
i
s
a
a
c
c
-		 1
1
2		 8
1
0
5
,		 0
3
1

International Organic Revenue Growth of 13%cc

Q
1
2
0
0
8		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 3
%
+		 2
%
+		 1
3
%
+
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 3
9
%
+		 2
%
7
+		 1
%
7
+
R
t
t
t
e
v
e
n
u
e
p
e
r
r
e
a
m
e
n		 1
)
\$
3
2
2		 \$
1
6
8
G
h
t
r
o
w		 1
%
-		 5
%
+
c
c
C
l
i
i
Q
1
2
0
0
8
n
c
s		 2
2
9
7
,		 1
6
4
0
,		 6
5
7
G
h
t
r
o
w		 %
5
+		 4
%
+		 6
%
+
Q
D
1
e
n
o
o
s
v
(
in
lu
d
in
d
l
in
ic
)
c
g
m
a
na
g
e
c
s		 4
4		 2
9		 1
5

1) including Mexico

cc = constant currency

Deutsche Bank German Corporate Conference, June 4, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA 28

Strong Quality Performance Except for Hemoglobin Impact in North America

N
h
A
t
o
r		 i
m
e
r
c
a		 E M
E
A
f
%
F
M
E
i
t
t
o
p
a
e
n
s		 Q
1
2
0
0
7		 Q
1
2
0
0
8		 Q
1
2
0
0
7		 Q
1
2
0
0
8
/
K
t
V
≥
1
2		 9
3
%		 %
9
5		 9
4
%		 %
9
5
H
l
b
i
≥
1
1
/
d
l
e
m
o
g
o
n
g		 8
2
%		 4
%
7		 1
%
7		 6
9
%
/
A
l
b
i
≥
3
5
d
l
m
n
g
u		 7
9
%		 8
0
%		 8
4
%		 8
3
%
P
h
h
3
/
d
l
t
5
5
5
o
s
p
a
e
m
g
-		 1
%
5		 %
5
3		 8
%
5		 %
5
7
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 *
1
1
3		 *
1
0
7		 8
4		 8
0

Continued reduction in hospital days

* The hospitalization rates for the US reflects FMS adoption of CMS policy

Quality Outcomes - United States

Anemia Management

Data Source: Clinical Performance Management (CPM) Data / Legacy FME U.S. clinics

Quality Outcomes - United States

EPO Utilization

Data Source: Clinical Performance Management (CPM) Data / Legacy FME U.S. clinics

Deutsche Bank German Corporate Conference, June 4, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA

Days Sales Outstanding (DSO)

Best in Industry

\$
i
i
l
l
i
n
m
o
n
s		 Q
1
2
0
0
7		 Q
1
2
0
0
8		 G
h
t
r
o
w
)
1
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
e
o
p
e
r
a
n
g
a
c
e
s
v
y
v		 2
8
3		 1
9
2
6
%
f r
7.
o
ev
e
nu
e		 (
)
3
2
%
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
1
0
9		 (
)
1
5
4
C
F
h
F
l
r
e
e
a
s
o
w		 1
7
4		 3
8		 (
)
7
8
%
1)
A
i
i
i
f
d
i
i
t
t
t
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 (
)
9
0		 (
3
2
)
C
F
h
F
l
r
e
e
a
s
o
w
f
i
i
i
t
t
a
e
r
a
c
q
s
o
n
s
u		 8
4		 6

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Debt and EBITDA Development

•including non-cash charges

pf = pro forma excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics ltm = last twelve months cl = closing RCG A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Financial Cushion

\$
i
i
l
l
i
n
m
o
n
s		 F
i
l
i
t
a
c
y		 1
)
U
t
i
l
i
t
i
z
a
o
n		 C
h
i
u
s
o
n
C
d
i
A
t
t
r
e
g
r
e
e
m
e
n		 4
1
2
8
,		 3
2
0
7
,		 8
8
5
T
P
f
d
S
i
i
t
t
r
s
r
e
e
r
r
e
e
c
r
e
s
u
u		 6
9
9		 6
9
9		 0
B
d
2
0
0
2
0
1
7
7
o
n
–		 0
0
5		 0
0
5		 0
(
S
)
N
h
l
d
h
i
d
l
h
t
o
e
s
c
s
c
e
n
a
r
e
e
n
u		 3
1
6		 3
1
6		 0
E
I
B
F
i
l
i
t
a
c
y		 3
4
9		 1
9
1		 0
2
)
O
h
b
k
f
i
l
i
i
t
t
e
r
a
n
a
c
e
s		 4
3
5		 1
9
7		 2
6
5
S
b
l
t
t
u
o
a		 6
4
4
5
,		 1
3
5
7
,		 1
1
1
4
,
A
R
i
b
l
P
t
c
c
o
u
n
s
e
c
e
v
a
e
r
o
g
r
a
m
3
)
N
h
A
i
t
o
r
m
e
r
c
a		 6
2
0		 5
7
7		 4
3
O
T
T
A
L		 7
0
6
5
,		 5
7
5
0
,		 1
1
5
7
,

1 ) Utilization may differ from Balance Sheet debt due to off-balance sheet items

2 ) As of December 31, 2007

3 ) \$ 650 million facility amount, limit represents maximum amount of eligible receivables

Deutsche Bank German Corporate Conference, June 4, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA

Current Debt Maturity

M
h
3
1
2
0
0
8
a
r
c
,

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

E
t
l
R
e
r
n
a
e
e
n
e
x
v
u		 Q
1
2
0
0
8		 Q
1
2
0
0
7		 t
h
g
ro
w		 cc
In
t
t
io
l
du
t
e
rn
a
na
p
ro
c
re
ve
nu
e		 5
6
6		 4
5
9		 2
3
%
+		 1
0
%
+
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
)
7
1		 (
)
5
2
Ex
t
l r
=
e
rn
a
ev
e
nu
e		 4
9
5		 4
0
7		 %
2
2
+		 %
9
+
No
h
A
ic
du
t
t
r
m
e
r
a
p
ro
c
re
ve
nu
e		 3
0
3		 2
8
1		 8
%
+
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
)
1
3
1		 (
)
1
2
8
Ex
t
l r
=
e
rn
a
ev
e
nu
e		 1
7
2		 1
5
3		 %
1
2
+
T
O
T
A
L
du
t
p
ro
c
re
ve
nu
e		 8
6
9		 7
4
0		 1
7
%
+		 9
%
+
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
2
0
2
)		 (
1
8
0
)
Ex
t
l r
=
e
rn
a
ev
e
nu
e		 6
6
7		 5
6
0		 1
9
%
+		 1
0
%
+
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 Q
1
2
0
0
8		 Q
1
2
0
0
7
Pu
ha
f p
la
d
ip
ty
t
t
rc
s
e
o
ro
p
e
r
p
n
a
n
e
q
m
e
n
u
,		 1
6
0		 1
1
7
Pr
d
fr
le
f p
ty
la
t
d
ip
t
o
c
e
e
s
o
m
s
a
o
ro
p
e
r
p
n
a
n
e
q
u
m
e
n
-
,		 (
6
)		 (
8
)
C
(
)
i
l e
d
i
t
tu
t
a
p
a
xp
e
n
re
ne
=		 1
5
4		 1
0
9

cc = constant currency

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

D
b
t
e		 Q
1
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4
S
ho
t
te
bo
in
r
rm
rro
w
g
s		 7
0
7		 2
1
7		 3
3
1		 1
5
1		 4
1
9
S
ho
t
te
bo
in
fro
la
te
d
t
ies
+
r
rm
rro
g
s
m
re
p
ar
w		 1
1		 2 5 1
9		 6
Cu
t p
t
io
f
lo
-te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
io
+
rre
n
or
n
o
ng
rm
n
ca
p
se
o
a
ns		 1
1
9		 8
5		 1
6
0		 1
2
6		 2
3
0
Cu
io
f
Tr
Pr
fe
d
Se
i
ies
t p
t
t
t
+
rre
n
or
n
o
us
e
rre
cu
r		 - 6
7
0
Lo
-te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
io
les
t p
t
io
+
ng
rm
n
ca
p
se
o
a
ns
s
cu
rre
n
or
n
,		 4,
1
5
6		 4,
0
0
4		 3,
8
2
9		 7
0
7		 5
4
5
Tr
t
Pr
fe
d
Se
i
t
ies
(
t o
f c
t p
t
io
)
+
us
e
rre
cu
r
ne
ur
re
n
or
n		 6
9
7		 6
6
4		 1,
2
5
4		 1,
1
8
8		 1,
2
7
9
T
l
d
b
t
t
o
a
e
=		 6
9
0
5,		 6
4
2
5,		 9
5,
5
7		 2,
1
9
1		 2,
4
9
7
E
B
I
T
D
A		 Q
1
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4
(
p
ro
for
)
ma
lve
hs
in
in
(
E
B
I
T
)
La
t
tw
t
t
s
e
m
on
o
p
er
a
g
co
m
e		 1,
6
0
4		 1,
8
0
5		 1,
3
6
7		 9
3
9		 8
2
5
La
t
tw
lve
t
hs
de
ia
t
io
d
t
iza
t
io
+
s
e
m
on
p
re
c
n
an
am
or
n		 3
7
5		 3
6
3		 3
2
6		 2
5
1		 2
3
3
No
h
ha
+
n-
ca
s
c
rg
es		 4
1		 4
1		 3
5		 1
4		 1
3
(
)
E
B
I
T
D
A
l
ize
d
an
nu
a
=		 2,
0
2
0		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8
C
h
F
l
a
s
o
w		 Q
1		 2
0
0
8		 Q
1
2
0
0
7
Ac
is
i
io
t
q
u
ns		 (
1
)
7		 (
9
0
)
Pr
d
fro
d
ive
i
t
tu
o
c
e
e
s
m
s
re
s		 3
9		 -
f
A
is
i
t
io
t
d
iv
t
i
tu
c
q
u
ns
ne
o
e
s
re
s
,		 (
)
3
2		 (
)
9
0

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 Email: [email protected] Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

For recent updates, please have a look at our new webpage. Navigation around www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Share

More from Fresenius Medical Care AG & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.